Enfuvirtide (T-20)

Category : Virus Peptide

Purity : 95%

Sequence (One Letter Code) : Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2

Sequence (Three letter Code) : Ac-{TYR}{THR}{SER}{LEU}{ILE}{HIS}{SER}{LEU}{ILE}{GLU}{GLU}{SER}{GLN}{ASN}{GLN}{GLN}{GLU}{LYS}{ASN}{GLU}{GLN}{GLU}{LEU}{LEU}{GLU}{LEU}{ASP}{LYS}{TRP}{ALA}{SER}{LEU}{TRP}{ASN}{TRP}{PHE}-NH2

36 residue synthetic peptide that inhibits HIV-1 fusion with CD4 cells. N-terminal acetylated, C-terminal amide. Enfuvirtide is the first in this class to reach market approval. Fusion inhibitors block the last step in the three-step viral entry process consisting of attachment, co-receptor binding and fusion, thereby preventing viral capsid entry into the host cell. Enfuvirtide has a unique mechanism of action and high viral target specificity, and in clinical trials has been shown to exhibit both high efficacy and low toxicity. Enfuvirtide is a peptide mimetic of an essential region within viral envelope glycoprotein gp41 that functions by blocking gp41 structural rearrangements at a transitional pre-fusion conformation.

Mol Wt : 4491.88